Demonstrates leadership in AI driven pharma through Accenture partnership

Bristol Myers Squibb, one of the world’s largest
biopharmaceutical companies, and Accenture, a global professional services firm, today
announced the official opening of a new AI-powered content hub, ‘Mosaic’, in Mumbai,
India.

The first-of-its-kind, end-to-end, generative AI-enabled content hub will accelerate
Bristol Myers Squibb’s commercialization through enhanced digital capabilities, which
will help identify physician’s educational needs in real-time, enabling rapid creation of
patient-centric content.

The Mosaic content hub was officially launched today in Mumbai by Adam Lenkowsky,
Chief Commercialization Officer of Bristol Myers Squibb and Ndidi Oteh, global CEO of
Accenture Song.

“The future of healthcare is about meeting clinicians and patients where they are and
doing so in meaningful ways. This partnership reflects our BMS approach to end-to-end
digital transformation,” said Adam Lenkowsky, Chief Commercialization Officer, Bristol
Myers Squibb. “The Mosaic content hub will ultimately improve patient experience by
making it easier for our marketing teams to create and share timely, tailored
communications with health care professionals.”

Bristol Myers Squibb has a strong presence in India through its commercial operations
for more than two decades, offering medicines in oncology, hematology, and cardiology.
The company also opened a cutting-edge facility in Hyderabad recently, home to more
than 3,000 Business Insights and Technology, Global Drug Development, Global Product
Development and Supply, Enabling Functions employees. BMS is investing $130 million
to advance a portfolio of AI initiatives and AI-enabled capabilities across marketing.
The Mosaic content hub represents a component of this investment. Bristol Myers
Squibb is tapping into the region’s collaborative spirit and digital expertise, making it a
strategic center for developing and scaling next-generation, AI-driven solutions
across its global operations. 

Bristol Myers Squibb’s science-powered and patient-centric mission is accelerating,
driven in part by transformational advancements in artificial intelligence and machine
learning (AI/ML). “We are strategically leveraging and integrating AI tools across BMS to
unlock efficiency, enable access to data, boost productivity and enhance decision-
making – all with the goal of helping our global workforce reinvent our industry.” said
Anvita Karara, Vice President, Worldwide Commercialization Excellence.
Bristol Myers Squibb and Accenture have built a trusted partnership for more than 25
years, united by a shared commitment to innovation and operational excellence. What

began as traditional service delivery has evolved into a powerful engine for digital
transformation, with Accenture bringing top talent and capabilities to support Bristol
Myers Squibb’s most important priorities.

The partnership with Accenture to launch a content hub in Mumbai will bring together a
large team of creatives and technologists to modernize and reinvent how we develop
and deliver marketing content at scale. “Accenture and Bristol Myers Squibb are
leading the AI-forward reinvention of biopharma by applying innovative technologies to
generate meaningful outcomes for patients. Mosaic is a powerful example of how
Bristol Myers Squibb is driving industry transformation and setting a new standard for
hyper-personalized experiences for healthcare professionals,” said Accenture Song’s
CEO, Ndidi Oteh.